Advertisement
BCDA vs XRTX
Which Stock Would AI Choose? BioCardia (BCDA) vs. XORTX Therapeutics (XRTX) Stock Comparison
Key Takeaways
- Both BCDA and XRTX are clinical-stage biotechnology companies, but they operate in different therapeutic areas and are at different points in their corporate lifecycles.
- BCDA is advancing toward near-term regulatory submissions in cardiovascular cell therapy, while XRTX is reprioritizing around its gout program after significant restructuring and share-price pressure.
- Recent financing activity, share-count changes, and momentum differ meaningfully, creating a clear contrast in risk profile and relative performance.
- Tickeron AI Verdict: Based on trend consistency, catalyst visibility, and stability, the AI currently favors BCDA over XRTX.
- For deeper context, explore BCDA Major News and BCDA Today's Price Move, plus XRTX Major News and XRTX Today's Price Move.
- To see which AI-powered strategies are currently best suited to this market, explore Trending AI Robots.
Introduction
Small- and micro-cap biotechnology stocks offer distinct risk-reward profiles that appeal to traders and investors comfortable with volatility and binary, catalyst-driven outcomes. This stock comparison examines BCDA and XRTX, two clinical-stage developers whose relative performance has diverged in recent market activity. BioCardia is pursuing cardiovascular cell therapies with multiple regulatory milestones ahead, while XORTX Therapeutics is refocusing its pipeline on a single gout program following a period of restructuring. Comparing their business models, recent momentum, and market positioning can help readers assess where each company stands today.
BCDA Overview and Recent Performance
BCDA, or BioCardia, Inc., is a Sunnyvale, California-based clinical-stage regenerative medicine company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead candidate, CardiAMP, is an autologous cell therapy for ischemic heart failure and refractory angina, complemented by the CardiALLO allogeneic stem cell platform and the Helix transendocardial delivery system.
In recent weeks, the company has advanced its regulatory path on multiple fronts. BioCardia completed its clinical consultation process with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for the CardiAMP system, moving toward a marketing approval application targeted for late 2026. It also announced U.S. Food and Drug Administration (FDA) acceptance of a pre-submission package for the Helix catheter. The company raised roughly $4.4 million in financing during the period, extending its cash runway into early 2027. The stock has traded in a range near its 52-week low, with its share price reflecting the ongoing cash needs and execution risk typical of pre-revenue biotech.
XRTX Overview and Recent Performance
XRTX, or XORTX Therapeutics Inc., is a Calgary, Canada-based late-stage pharmaceutical company focused on therapies for diseases driven by aberrant purine metabolism and elevated uric acid. Its lead program, XRx-026, targets gout using XORLO, a proprietary formulation of oxypurinol; earlier-stage programs address autosomal dominant polycystic kidney disease (ADPKD), acute kidney injury, and diabetic nephropathy.
The company has undergone significant structural change in recent months. XORTX completed a 5-for-1 reverse share split and a roughly $5 million public offering, and it elected to voluntarily delist from the TSX Venture Exchange while maintaining its Nasdaq listing. Management has prioritized the gout program, announcing plans to submit an Investigational New Drug (IND) application to the FDA and a Clinical Trial Application (CTA) to Health Canada, alongside the initiation of clinical and commercial manufacturing. Despite these catalysts, the share price has declined substantially from its 52-week high, and the stock carries elevated short interest, reflecting market skepticism about execution and financing.
Trending AI Robots
For traders seeking a data-driven alternative to manual stock selection, Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots designed to navigate shifting market conditions. Tickeron hosts a large library of AI trading bots that collectively monitor thousands of tickers, each with its own trading style, strategy, timeframe, and performance statistics. Rather than surfacing the entire catalog, the Trending AI Robots section highlights only the strategies currently best aligned with prevailing market conditions, giving users a focused, professionally maintained shortlist. Reviewing this curated list can help traders identify approaches whose recent performance and risk parameters suit their objectives.
Head-to-Head Comparison
The two companies diverge across several dimensions. In terms of business model, BCDA pairs a therapeutic cell platform with a proprietary delivery device, creating a potential dual-product opportunity, whereas XRTX is concentrating on a repurposed small-molecule formulation with a narrower near-term commercial focus.
On growth drivers, BCDA's momentum stems from regulatory consultations in both Japan and the United States, while XRTX's hinges on executing an IND and CTA submission for gout. Risk factors also differ: BCDA faces clinical-enrollment and cash-burn risk, while XRTX contends with a reverse split, share dilution from recent offerings, an exchange delisting, and a falling share price accompanied by meaningful short interest.
In market positioning, BCDA retains analyst coverage with a comparatively larger market capitalization and a less volatile recent trajectory. XRTX's smaller capitalization, reduced share count, and concentrated pipeline make it more sensitive to any single news event.
Tickeron AI Verdict
Weighing trend consistency, catalyst visibility, and relative stability, Tickeron's AI currently leans toward BCDA as the more favorable of the two. BCDA's multiple regulatory milestones, comparatively steadier price action, and diversified therapeutic-plus-device platform provide a clearer and more balanced catalyst profile. By contrast, XRTX's ongoing restructuring, financing-driven dilution, and elevated short interest introduce additional uncertainty that tends to weigh against trend consistency. This assessment reflects observable positioning rather than a definitive forecast, and conditions could shift as new data emerges.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCDA is a Hold and XRTX is a Hold.
BCDA's RSI Oscillator ascends from oversold territory
The RSI Oscillator for BCDA moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 27 of the 31 cases the stock moved higher. This puts the odds of a move higher at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 64 cases where BCDA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for BCDA just turned positive on November 10, 2026. Looking at past instances where BCDA's MACD turned positive, the stock continued to rise in 38 of 47 cases over the following month. The odds of a continued upward trend are 81%.
Following a +9.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCDA advanced for three days, in 183 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
BCDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BCDA as a result. In 95 of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
BCDA moved below its 50-day moving average on October 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BCDA crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for BCDA entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. BCDA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.766) is normal, around the industry mean (3.498). P/E Ratio (-1.441) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.090) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2000.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Momentum Indicator for XRTX turns negative, indicating new downward trend
XRTX saw its Momentum Indicator move below the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 107 similar instances where the indicator turned negative. In 100 of the 107 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for XRTX entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where XRTX's RSI Indicator exited the oversold zone, 31 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for XRTX just turned positive on November 02, 2026. Looking at past instances where XRTX's MACD turned positive, the stock continued to rise in 42 of 50 cases over the following month. The odds of a continued upward trend are 84%.
Following a +5.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where XRTX advanced for three days, in 154 of 183 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
XRTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.300) is normal, around the industry mean (3.498). P/E Ratio (-0.353) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. XRTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XRTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
BCDA | XRTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 55 | 52 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 87 Overvalued | 43 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 99 | |
PRICE GROWTH RATING 1..100 | 61 | 92 | |
P/E GROWTH RATING 1..100 | 36 | 9 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XRTX's Valuation (43) in the null industry is somewhat better than the same rating for BCDA (87). This means that XRTX’s stock grew somewhat faster than BCDA’s over the last 12 months.
XRTX's Profit vs Risk Rating (100) in the null industry is in the same range as BCDA (100). This means that XRTX’s stock grew similarly to BCDA’s over the last 12 months.
XRTX's SMR Rating (99) in the null industry is in the same range as BCDA (100). This means that XRTX’s stock grew similarly to BCDA’s over the last 12 months.
BCDA's Price Growth Rating (61) in the null industry is in the same range as XRTX (92). This means that BCDA’s stock grew similarly to XRTX’s over the last 12 months.
XRTX's P/E Growth Rating (9) in the null industry is in the same range as BCDA (36). This means that XRTX’s stock grew similarly to BCDA’s over the last 12 months.
| BCDA | XRTX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 87% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 84% | 1 day ago 88% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 81% | 1 day ago 84% |
| TrendWeek ODDS (%) | 1 day ago 80% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 90% |
| Advances ODDS (%) | 3 days ago 78% | 1 day ago 84% |
| Declines ODDS (%) | 7 days ago 88% | 4 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 80% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 85% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BCDA’s FA Score shows that 0 FA rating(s) are green while XRTX’s FA Score has 1 green FA rating(s).
- BCDA’s FA Score: 0 green, 5 red.
- XRTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BCDA’s TA Score shows that 5 TA indicator(s) are bullish while XRTX’s TA Score has 5 bullish TA indicator(s).
- BCDA’s TA Score: 5 bullish, 5 bearish.
- XRTX’s TA Score: 5 bullish, 3 bearish.
Price Growth
BCDA (@Biotechnology) experienced а +0.94% price change this week, while XRTX (@Biotechnology) price change was -10.09% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
BCDA is expected to report earnings on Nov 12, 2026.
XRTX is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
BCDA and
Correlation & Price change
A.I.dvisor indicates that over the last year, BCDA has been loosely correlated with XRTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if BCDA jumps, then XRTX could also see price increases.
| Ticker / NAME | Correlation To BCDA | 1D Price Change % | ||
|---|---|---|---|---|
| BCDA | 100% | -0.91% | ||
| XRTX - BCDA | 43% Loosely correlated | +4.72% | ||
| MDGL - BCDA | 29% Poorly correlated | +0.10% | ||
| INO - BCDA | 28% Poorly correlated | +1.72% | ||
| KOD - BCDA | 28% Poorly correlated | +1.18% | ||
| AUPH - BCDA | 27% Poorly correlated | -0.55% | ||
More | ||||
XRTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, XRTX has been loosely correlated with BCDA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if XRTX jumps, then BCDA could also see price increases.
| Ticker / NAME | Correlation To XRTX | 1D Price Change % | ||
|---|---|---|---|---|
| XRTX | 100% | +4.72% | ||
| BCDA - XRTX | 43% Loosely correlated | -0.91% | ||
| BYSI - XRTX | 26% Poorly correlated | +11.06% | ||
| CLNN - XRTX | 26% Poorly correlated | -4.88% | ||
| MIST - XRTX | 26% Poorly correlated | N/A | ||
| DOMH - XRTX | 24% Poorly correlated | +7.61% | ||
More | ||||